60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO]

Side Effects & Adverse Event Reports


View Chart Data

32.8K

Adverse Events

90.8K

Side Effects

2012

Data Starting In

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO].

Understanding the potential Side Effects and Adverse Events of 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO] is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO] may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO] are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO]?

    SymPedia shows 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO] adverse event reports for 32,811.

  • How many side effects have been reported for 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO]?

    SymPedia shows 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO] side effect reports for 90,764.

  • What year does the 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO] reporting data start?

    SymPedia reporting data on this page starts in 2012.

  • What years are included in the yearly chart for 60 ACTUAT TESTOSTERONE 12.5 MG/ACTUAT TOPICAL GEL [VOGELXO]?

    SymPedia yearly chart data on this page covers 2012 to 2025.